Dr. Steven J. Gedde, MD

Dr. Gedde practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Gedde's NPI, 1740223361, was assigned on June 13, 2006. Dr. Gedde graduated from Vanderbilt University School Of Medicine in 1991. Dr. Gedde holds Florida license ME68688.

Dr. Gedde's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Gedde's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Gedde to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gedde practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Gedde's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Gedde is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Gedde's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, glaucoma, glaucoma surgery and inflammation of iris among the conditions Dr. Gedde treats.

CMS data shows 1,156 Medicare services from Dr. Gedde across 4 procedure codes in 2024, for 336 Medicare patients. Medicare paid $44,760 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 336 Medicare patients who saw Dr. Gedde in 2024. The largest group is 75 to 84, with 151 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gedde's median patient age at 79, with 57% women.

In 2024, Dr. Gedde wrote 3,585 Medicare Part D claims for 444 patients. 62% of them were for generic drugs. CMS names the drug for 3,506 of them, across 27 drugs with 11 or more claims each, at $288,060 in total drug cost. In 2023, CMS named 3,956 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Gedde for performance year 2024, reported as part of a group. Dr. Gedde accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 145 papers to Dr. Gedde, published from 2004 to 2025. 2020 was the busiest year, with 13. The most frequent topics are Intraocular Pressure, Glaucoma and Glaucoma Drainage Implants. Dr. Gedde has published most often in Am J Ophthalmol. Dr. Gedde's most frequent co-authors are Donald Lyle Budenz, MD, Richard K. Parrish, MD and Kateki Vinod, MD.

Dmand AI links Dr. Gedde to 3 clinical trials. Conditions studied include Glaucoma and Ocular Hypertension. University of Miami sponsors the most, 3.

CMS Open Payments shows 7 general payments to Dr. Gedde from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Alcon Laboratories Inc paid the most, $172.

Dmand AI lists 3 awards for Dr. Gedde, most recently CMS Stage 1 EHR in 2014.

Dr. Gedde graduated from Vanderbilt University School Of Medicine in 1991. Dr. Gedde is a member of AAO.

Dr. Gedde is in network with 11 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.